Advanced Materials,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 10, 2024
Abstract
The
pioneering
work
on
liposomes
in
the
1960s
and
subsequent
research
controlled
drug
release
systems
significantly
advances
development
of
nanocarriers
(NCs)
for
delivery.
This
field
is
evolved
to
include
a
diverse
array
such
as
liposomes,
polymeric
nanoparticles,
dendrimers,
more,
each
tailored
specific
therapeutic
applications.
Despite
significant
achievements,
clinical
translation
limited,
primarily
due
low
efficiency
delivery
an
incomplete
understanding
nanocarrier
interactions
with
biological
systems.
Addressing
these
challenges
requires
interdisciplinary
collaboration
deep
nano‐bio
interface.
To
enhance
design,
scientists
employ
both
physics‐based
data‐driven
models.
Physics‐based
models
provide
detailed
insights
into
chemical
reactions
at
atomic
molecular
scales,
while
leverage
machine
learning
analyze
large
datasets
uncover
hidden
mechanisms.
integration
presents
harmonizing
different
modeling
approaches
ensuring
model
validation
generalization
across
However,
this
crucial
developing
effective
targeted
By
integrating
enhanced
data
infrastructure,
explainable
AI,
computational
advances,
potentials,
researchers
can
develop
innovative
nanomedicine
solutions,
ultimately
improving
outcomes.
Cells,
Год журнала:
2024,
Номер
13(5), С. 436 - 436
Опубликована: Март 1, 2024
Lung
cancer
remains
a
formidable
global
health
challenge
that
necessitates
inventive
strategies
to
improve
its
therapeutic
outcomes.
The
conventional
treatments,
including
surgery,
chemotherapy,
and
radiation,
have
demonstrated
limitations
in
achieving
sustained
responses.
Therefore,
exploring
novel
approaches
encompasses
range
of
interventions
show
promise
enhancing
the
outcomes
for
patients
with
advanced
or
refractory
cases
lung
cancer.
These
groundbreaking
can
potentially
overcome
resistance
offer
personalized
solutions.
Despite
rapid
evolution
emerging
therapies,
persistent
challenges
such
as
resistance,
toxicity,
patient
selection
underscore
need
continued
development.
Consequently,
landscape
therapy
is
transforming
introduction
precision
medicine,
immunotherapy,
innovative
modalities.
Additionally,
multifaceted
approach
involving
combination
therapies
integrating
targeted
agents,
immunotherapies,
traditional
cytotoxic
treatments
addresses
heterogeneity
while
minimizing
adverse
effects.
This
review
provides
brief
overview
latest
are
reshaping
treatment.
As
these
progress
through
clinical
trials
integrated
into
standard
care,
potential
more
effective,
targeted,
comes
focus,
instilling
renewed
hope
facing
challenging
diagnoses.
Molecular Pharmaceutics,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 13, 2025
The
high
content
of
vitamin
E,
including
tocopherols
and
tocotrienols
(TCF-TTE),
in
palm
oil
(Elaeis
guineensis)
has
made
it
a
promising
candidate
for
the
alternative
treatment
atopic
dermatitis
(AD).
However,
limited
solubility
TCF-TTE
restricted
its
therapeutic
efficacy.
In
this
study,
pluronic-based
micelles
(MCs)
encapsulating
oil-derived
were
formulated
with
dissolvable
microarray
patch-micelles
(DMP-MC)
using
carboxymethyl
cellulose
(CMC)
synthesized
from
empty
fruit
bunches
to
optimize
delivery
AD.
MC
was
prepared
direct
dissolution
method
Pluronic
F68
F127.
results
showed
that
increased
TCF-TTE,
which
further
confirmed
by
an
vitro
study
where
90.23
±
2.07%
TCF
4.56
1.36%
TTE
released
compared
unencapsulated
extract.
Furthermore,
CMC
biopolymers
integrated
into
DMP-MC
polyvinylpyrrolidone
(PVP)
exhibited
favorable
physical
properties,
such
as
mechanical
strength
penetration
ability.
also
better
platform
lower
permeation,
indicating
higher
retention
localized
effects
on
AD
skin
than
cream-MC.
Additionally,
dermatokinetic
profile
parameters
significant
improvement.
mean
residence
time
(MRT)
parameter
indicated
retained
longer
times
19.28
0.02
h
20.68
0.01
h.
Moreover,
vivo
revealed
could
relieve
symptoms
more
rapidly
oral
doses
cream-MC,
proved
be
efficient.
no
tissue
destruction
(granulation
fibrosis)
rats
treated
seventh
day.
Therefore,
successfully
developed
formula
formulation
CMC,
potentially
improve
AD's
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(18), С. 14044 - 14044
Опубликована: Сен. 13, 2023
Alzheimer’s
disease
(AD)
is
a
progressive
neurodegenerative
that
affects
most
people
worldwide.
AD
complex
central
nervous
system
disorder.
Several
drugs
have
been
designed
to
cure
AD,
but
with
low
success
rates.
Because
the
blood–brain
and
blood–cerebrospinal
fluid
barriers
are
two
protect
system,
their
presence
has
severely
restricted
efficacy
of
many
treatments
studied
for
diagnosis
and/or
therapy.
The
use
nanoparticles
treatment
focus
an
established
rapidly
developing
field
nanomedicine.
Recent
developments
in
nanomedicine
made
it
possible
effectively
transport
brain.
However,
numerous
obstacles
remain
successful
nanomedicines
clinical
settings
treatment.
Furthermore,
given
rapid
advancement
therapeutics,
better
outcomes
patients
can
be
anticipated.
This
article
provides
overview
recent
using
different
types
management
AD.
Advancing
therapeutic
progress
is
centered
on
developing
drug
delivery
systems
(DDS)
that
control
molecule
release,
ensuring
precise
targeting
and
optimal
concentrations.
Targeted
DDS
enhances
treatment
efficacy
minimizes
off-target
effects,
but
struggles
with
degradation.
Over
the
last
three
decades,
nanopharmaceuticals
have
evolved
from
laboratory
concepts
into
clinical
products,
highlighting
profound
impact
of
nanotechnology
in
medicine.
Despite
advancements,
effective
therapeutics
remains
challenging
because
biological
barriers.
Nanocarriers
offer
a
solution
small
size,
high
surface-to-volume
ratios,
customizable
properties.
These
address
physiological
challenges,
such
as
shear
stress,
protein
adsorption,
quick
clearance.
They
allow
targeted
to
specific
tissues,
improve
outcomes,
reduce
adverse
effects.
exhibit
controlled
decreased
degradation,
enhanced
efficacy.
Their
size
facilitates
cell
membrane
penetration
intracellular
delivery.
Surface
modifications
increase
affinity
for
types,
allowing
This
study
also
elucidates
potential
integration
artificial
intelligence
nanoscience
innovate
future
nanocarrier
systems.
Lung
cancer
remains
a
formidable
global
health
challenge
that
necessitates
inventive
strategies
to
improve
therapeutic
outcomes.
Conventional
treatments,
including
surgery,
chemotherapy,
and
radiation,
have
demonstrated
limitations
in
achieving
sustained
responses.
Therefore,
the
explora-tion
of
novel
approaches
encompasses
range
interventions
show
promise
enhancing
outcomes
for
patients
with
lung
cancer,
particularly
those
facing
advanced
or
refractory
cases.
These
groundbreaking
hold
potential
overcome
resistance
offer
personalized
solutions.
Despite
rapid
evolution
emerging
therapies,
persistent
challenges
such
as
resistance,
toxicity,
patient
selection
underscore
need
continued
development.
Consequently,
landscape
therapy
is
transforming
in-troduction
precision
medicine,
immunotherapy,
innovative
modalities.
Addi-tionally,
multifaceted
approach
involving
combination
therapies
through
integration
tar-geted
agents,
immunotherapies,
traditional
cytotoxic
treatments
addresses
heterogeneity
while
minimizing
adverse
effects.
This
review
provides
brief
overview
latest
are
reshaping
treatment.
As
these
progress
clinical
trials
integrate
into
standard
care,
more
effective,
targeted,
comes
focus,
instilling
renewed
hope
challenging
diagnoses.
Medical Sciences,
Год журнала:
2024,
Номер
12(2), С. 20 - 20
Опубликована: Апрель 7, 2024
Lung
cancer
remains
the
leading
cause
of
cancer-related
deaths,
with
a
poor
prognosis.
Of
two
types,
non-small
cell
lung
(NSCLC)
is
major
and
most
prevalent
type
associated
low
response
rates
to
current
treatment
options.
Sorafenib,
multitargeted
tyrosine
kinase
inhibitor
used
for
various
malignancies,
gained
attention
its
potential
efficacy
in
NSCLC.
This
review
paper
focuses
on
findings
recent
vitro,
vivo,
clinical
studies
regarding
sorafenib.
Overall,
sorafenib
has
shown
definitive
therapeutic
NSCLC
lines,
xenografts,
human
subjects.
Novel
approaches
delivery
may
improve
should
be
focus
further
studies.
Current Gene Therapy,
Год журнала:
2024,
Номер
25(2), С. 92 - 112
Опубликована: Май 23, 2024
Lung
cancer
is
a
significant
cause
of
cancer-related
death
worldwide.
It
can
be
broadly
categorised
into
small-cell
lung
(SCLC)
and
Non-small
cell
(NSCLC).
Surgical
intervention,
radiation
therapy,
the
administration
chemotherapeutic
medications
are
among
current
treatment
modalities.
However,
application
chemotherapy
may
limited
in
more
advanced
stages
metastasis
due
to
potential
for
adverse
effects
lack
selectivity.
Although
small-molecule
anticancer
treatments
have
demonstrated
effectiveness,
they
still
face
several
challenges.
The
challenges
at
hand
this
context
comprise
insufficient
solubility
water,
bioavailability
specific
sites,
effects,
requirement
epidermal
growth
factor
receptor
inhibitors
that
genetically
tailored.
Bio-macromolecular
drugs,
including
small
interfering
RNA
(siRNA)
messenger
(mRNA),
susceptible
degradation
when
exposed
bodily
fluids
humans,
which
reduce
stability
concentration.
In
context,
nanoscale
delivery
technologies
utilised.
These
agents
offer
encouraging
prospects
preservation
regulation
pharmaceutical
substances,
addition
improving
medications.
Nanocarrier-based
systems
possess
notable
advantage
facilitating
accurate
sustained
drug
release,
as
opposed
traditional
systemic
methodologies.
primary
focus
scientific
investigation
has
been
augment
therapeutic
efficacy
nanoparticles
composed
lipids.
Numerous
techniques
implemented
treat
various
respiratory
ailments,
such
cancer.
exhibited
mitigate
limitations
associated
with
conventional
therapy.
As
an
illustration,
applying
nanocarriers
enhance
drugs
prevent
bio-macromolecular
drugs.
Furthermore,
these
devices
administer
controlled
extended
fashion,
thereby
augmenting
intervention's
effectiveness
reducing
reactions.
despite
promising
results,
remain
must
addressed.
Multiple
factors
necessitate
consideration
contemplating
medical
interventions.
To
begin
with,
advancement
efficient
methods
imperative.
addition,
comprehensive
toxicity
required.
Finally,
additional
research
needed
comprehend
treatments'
enduring
ramifications.
Despite
challenges,
field
nanomedicine
demonstrates
considerable
promise
enhancing
therapy
other
diseases.
